Skip to main content
TIBET AIM PHARM. INC. logo

TIBET AIM PHARM. INC. — Investor Relations & Filings

Ticker · 002826 ISIN · CNE100002C39 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,085 across all filing types
Latest filing 2022-05-06 Investor Presentation
Country CN China
Listing Shenzhen Stock Exchange 002826

About TIBET AIM PHARM. INC.

https://www.emyy.cn

Tibet Aim Pharm. Inc. is a pharmaceutical enterprise focused on the research, development, production, and distribution of medicinal products. The company integrates traditional Tibetan medicine with modern pharmaceutical manufacturing processes to develop a diverse portfolio of treatments. Its core product range typically includes cardiovascular medications, digestive system therapies, and specialized herbal formulations derived from high-altitude botanical sources. Tibet Aim Pharm. Inc. emphasizes the modernization of traditional formulas through rigorous clinical testing and standardized production techniques. The company serves healthcare providers and patients by providing therapeutic solutions that bridge ancient medical knowledge with contemporary scientific standards.

Recent filings

Filing Released Lang Actions
关于举办2021年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is a public announcement regarding the scheduling of the 2021 annual performance briefing (业绩说明会) by the company. It references that the 2021 Annual Report has already been disclosed on April 22, 2022, and invites investors to participate in the upcoming performance explanation meeting on May 12, 2022. The document does not contain the actual annual report or detailed financial data but serves as a notice about the event and invites questions from investors. This fits the description of an Investor Presentation (IP) as it focuses on a detailed presentation for investors about financial results and company performance, rather than the report itself or a simple announcement of report publication. The document length is short and it is not a certification or voting result. Therefore, the best classification is Investor Presentation (IP).
2022-05-06 Chinese
2022年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "西藏易明西雅医药科技股份有限公司 2022 年第一季度报告全文" which translates to "Tibet Yiming Xiya Pharmaceutical Technology Co., Ltd. 2022 First Quarter Report Full Text." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and explanations of financial changes for the first quarter of 2022. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for the quarter. It is not a brief announcement or a certification letter but a full financial report for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2022
2022-04-27 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a meeting resolution announcement from the Supervisory Board (监事会) of the company regarding the approval of the 2022 first quarter report. It states that the Supervisory Board reviewed and approved the quarterly report, confirming its compliance and accuracy. The document is short (643 characters) and primarily announces the resolution of the Supervisory Board meeting rather than containing the full quarterly report or detailed financial data. Therefore, it is not the Interim/Quarterly Report (IR) itself but an announcement related to the meeting and approval of that report. This fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2022-04-27 Chinese
董事会决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolutions passed at the company's third board meeting, specifically approving the company's 2022 first quarter report. It states that the board reviewed and agreed on the report's accuracy and compliance, but the document itself does not contain the financial report or detailed financial data. It also mentions that the actual 2022 first quarter report is disclosed elsewhere (on a website and newspapers). The document length is short (751 characters) and serves as a notice of the board meeting decisions rather than the report itself. Therefore, it fits the category of a Regulatory Filing (RNS) as a general announcement related to corporate governance and report approval, not the report itself (which would be an Interim/Quarterly Report IR).
2022-04-27 Chinese
2021年度监事会工作报告
Board/Management Information Classification · 95% confidence The document is titled as the "2021年度监事会工作报告" which translates to "2021 Supervisory Board Work Report". It details the supervisory board's activities, meetings, oversight of company operations, financial supervision, internal control evaluations, and other governance-related matters for the year 2021. It includes detailed descriptions of the supervisory board's work, including oversight of financial reports, internal controls, and compliance with laws and regulations. The document is a comprehensive report on the supervisory board's work rather than an announcement or a brief summary. It is not an annual report (10-K) or audit report (AR) but rather a management or supervisory report on governance and oversight activities. Given the content focuses on the supervisory board's work and governance oversight, the most appropriate classification is "Board/Management Information (MANG)". The document length (4852 characters) supports it being a full report rather than a brief announcement or certification. Confidence is high due to the detailed supervisory board report content and governance focus.
2022-04-22 Chinese
年度股东大会通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2021 Annual General Meeting (AGM) of the company 西藏易明西雅医药科技股份有限公司. It includes information about the meeting date, location, voting methods (both in-person and online), agenda items to be discussed and voted on, and instructions for shareholders on how to participate and vote. The document also contains the proxy form for shareholders to authorize representatives to vote on their behalf. The content is focused on informing shareholders about the AGM logistics and agenda rather than presenting financial results or reports. Therefore, this document fits the category of AGM Information (AGM-R). The document length is over 5,000 characters and contains detailed meeting information, not just an announcement of a report publication, so it is not an RPA. It is not a financial report or earnings release, nor a management or board change announcement. Hence, the classification is AGM-R with high confidence.
2022-04-21 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.